Executive Management

Dr. Vladimir Cmiljanovic

Dr. Vladimir Cmiljanovic

Chief Executive Officer

Dr. Vladimir Cmiljanovic is a renowned serial biotech entrepreneur, cancer scientist, and medicinal chemist with over 15 years of experience in oncology drug development.

Andreas Emmenegger

Andreas Emmenegger

Chief Financial Officer / Chief Business Officer

Andreas has more than 20 years of experience as the CFO of public and private multinational companies, including 15 years in the biotech industry.

Dr. Nadezda Gracheva

Dr. Nadezda Gracheva

Chief Operating Officer

Dr. Nadezda Gracheva is a scientist with a background in Radiochemistry and Radiopharmacy as a branch of Nuclear Medicine. She obtained a Ph.D. degree at ETH Zurich, where she was responsible for the development of novel radioactive nuclides for Targeted Radionuclide Therapy to promote innovative cancer treatments.

Prof. Dr. Andreas Türler

Prof. Dr. Andreas Türler

Chief Radiochemist

Prof. Dr. Andreas Türler is the Chief Radiochemist at Torpedo and publisher of 157 peer reviewed articles. Andreas has been a full professor at the University of Bern and head of the Laboratory of Radiochemistry at the Paul Scherrer Institute (LRC) for 15 years.

Dr. Lubor Gaal

Dr. Lubor Gaal

Global Head of Business Development

Lubor Gaal is a distinguished figure in the pharmaceutical and biotechnology industry. He currently serves as the Global Head of Business Development at Swiss Rockets and its subsidiary companies. With a career spanning over 25 years, Gaal has demonstrated exceptional expertise and leadership in various capacities across renowned organizations.

Dr. Bruno Osterwalder

Dr. Bruno Osterwalder

Chief Medical Officer

Dr. Bruno Osterwalder is an esteemed figure in the realm of hematology and oncology, with a wealth of experience spanning 15 years in academic clinical practice. With Swiss board certifications, his journey has been a testament to his expertise in internal medicine, hematology, and oncology.

Dr. Doriano Fabbro

Dr. Doriano Fabbro

Chief Scientific Officer

Dr. Doriano Fabbro is a renowned drug discovery and kinase expert with more than 20 years’ experience in the pharmaceutical industry, following 10 years in academia. Until 2005, Doriano was an Executive Director for the Oncology Drug Discovery Division of the Novartis Institute for Biomedical Research (NIBR) in Basel, Switzerland and was a member of the NIBR Oncology Advisory Board overseeing the oncology portfolio from target discovery to clinical development.

Dr. Milan Crnogorac

Dr. Milan Crnogorac

Chief Technology Officer

Dr. Milan Crnogorac is an experienced executive responsible for providing strategic, financial and operational leadership for the Technical Operations, Project Management and CapEx spending.

Dr. Paul Hebeisen

Dr. Paul Hebeisen

Head of Medicinal Chemistry

Dr. Paul Hebeisen is a highly experienced medicinal chemist with an impressive track record in drug discovery over 28 years of service at F. Hoffmann-La Roche AG, Switzerland. Paul served in various positions, most notably as a Group Leader in Chemistry in the discovery of novel anti-infectives.

Dr. Josef Künzle

Dr. Josef Künzle

Chief Quality Officer

Dr. Josef Künzle is an expert responsible for establishing and maintaining the company’s Pharmaceutical Quality Management System.

Dr. Aurélie Jenn

Dr. Aurélie Jenn

Head of Regulatory Affairs & Quality Assurance

Dr. Aurélie Jenn, Head of Regulatory Affairs and Quality Assurance, is a pharmacist (Pharm. D) bringing over 20 years of experience in the pharmaceutical industry. In a first part of her career, she worked in Regulatory Affairs / CMC writing for generic products and New Chemical Entities in Switzerland and France, having close interactions and providing support to technical departments.

David Allman

David Allman

Head of Clinical Operations

David Allman is a biochemist by training and has over 25 years of global experience in the pharmaceutical industry having worked for pharmaceutical companies and leading clinical research organizations as well as applying his expertise in the virtual development arena.

Dr. Emilie Frugier

Dr. Emilie Frugier

Head of Intellectual Property

Dr. Frugier is an experienced patent manager and a qualified European Patent Attorney with a focus on supporting small to mid-sized biotech entities in protecting and securing access to intellectual property assets critical to their competitiveness and fundraising.

Dr. Dirk Mossmann

Dr. Dirk Mossmann

Scientific Project Manager

Dr. Dirk Mossmann is a cancer biologist with broad expertise in mTOR signaling and cancer metabolism. He studied molecular medicine in Freiburg (Germany) and obtained his Ph.D. in the department of biochemistry.

Helene Muller

Helene Muller

Clinical Operations Manager

Helene Muller has over 25 years of experience in the pharmaceutical industry managing numerous clinical projects for leading clinical research organizations but also working as a consultant supporting mainly small and mid-sized biotechnology companies in project oversight and implementation.

Debora Foglia

Debora Foglia

Chief Legal Officer

Debora Foglia joined the company as Legal Counsel of Swiss Rockets AG and its subsidiary companies in January 2023. She is an attorney-at-law and holds a bachelor’s and master’s degree in law of the University of Basel.